Jeremiah R. Brown

Jeremiah R. Brown

Auto-generated profile, based on publicly available information

Jeremiah R. Brown

Audrey and Theodore Geisel School of Medicine at Dartmouth

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JBJeremiah R. Brown
Jeremiah R. Brown
RKRobert S. Kramer
Robert S. Kramer
SCSteven G. Coca
Steven G. Coca
CPChirag R. Parikh
Chirag R. Parikh

1 August 2010 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JBJeremiah R. Brown
Jeremiah R. Brown
JRJohn F. Robb
John F. Robb
CBClay A. Block
Clay A. Block
ASAnton C. Schoolwerth
Anton C. Schoolwerth
AKAaron V. Kaplan
Aaron V. Kaplan
DMDavid J. Malenka
David J. Malenka
Background—: Previous work on contrast-induced acute kidney injury (CI-AKI) has identified contrast volume as a risk factor and suggested that there is a maximum allowable contrast dose (MACD) above which the risk of CI-AKI is markedly increased. We hypothesized that there is a relationship between contrast volume and CI-AKI and that there might be reason to track incremental contrast volumes above and below the MACD limit. Methods and Results—: Consecutive patients undergoing percutaneous coronary intervention (PCI) were prospectively enrolled from 2000 to 2008 (n=10 065). Patients on dialysis before PCI were excluded (n=155). MACD was defined as (5 mL×body weight [kg])/baseline serum creatinine [mg/dL]) and divided into categories in which 1.0 reflects the MACD limit: ≤MACD ratios (MACD (1.0 to 1.5, 1.5 to 2.0, and >2.0). CI-AKI was defined as a ≥0.3 (mg/dL) or ≥50% increase in serum creatinine from baseline or new dialysis. Multivariable regression was conducted to evaluate the effect of exceeding the MACD on CI-AKI. Twenty percent of patients exceeded the MACD. Risk-adjusted CI-AKI increased by an average of 45% for each category exceeding the MACD (odds ratio, 1.45; 95% confidence interval, 1.29 to 1.62) Adjusted odds ratios for each category exceeding the MACD were 1.60 (95% confidence interval, 1.29 to 1.97), 2.02 (95% confidence interval, 1.45 to 2.81), and 2.94 (95% confidence interval, 1.93 to 4.48). CI-AKI for contrast dose <MACD showed no statistical difference ( P =0.5). Conclusions—: Contrast volume is a key risk factor for CI-AKI and matters the most in the highest-risk patient. The incremental use of contrast beyond the MACD is associated with an increased risk of CI-AKI.

1 November 2009 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
JBJeremiah R. Brown
Jeremiah R. Brown
CBClay A. Block
Clay A. Block
DMDavid J. Malenka
David J. Malenka
GOGerald T. O'Connor
Gerald T. O'Connor
ASAnton C. Schoolwerth
Anton C. Schoolwerth
CTCraig A. Thompson
Craig A. Thompson

1 January 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JBJeremiah R. Brown
Jeremiah R. Brown
MRMichael E. Rezaee
Michael E. Rezaee
EMEmily J. Marshall
Emily J. Marshall
MMMichael E. Matheny
Michael E. Matheny
Acute kidney injury (AKI) is a common reason for hospital admission and complication of many inpatient procedures. The temporal incidence of AKI and the association of AKI admissions with in-hospital mortality are a growing problem in the world today. In this review, we discuss the epidemiology of AKI and its association with in-hospital mortality in the United States. AKI has been growing at a rate of 14% per year since 2001. However, the in-hospital mortality associated with AKI has been on the decline starting with 21.9% in 2001 to 9.1 in 2011, even though the number of AKI-related in-hospital deaths increased almost twofold from 147,943 to 285,768 deaths. We discuss the importance of the 71% reduction in AKI-related mortality among hospitalized patients in the United States and draw on the discussion of whether or not this is a phenomenon of hospital billing (coding) or improvements to the management of AKI.

1 November 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JBJeremiah R. Brown
Jeremiah R. Brown
WHWilliam M. Hisey
William M. Hisey
EMEmily J. Marshall
Emily J. Marshall
DLDonald S. Likosky
Donald S. Likosky
ENElizabeth L. Nichols
Elizabeth L. Nichols
CPChirag R. Parikh
Chirag R. Parikh

1 September 2014 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
JBJeremiah R. Brown
Jeremiah R. Brown
RSRichard J. Solomon
Richard J. Solomon
MSMark J. Sarnak
Mark J. Sarnak
PMPeter A. McCullough
Peter A. McCullough
MSMark E. Splaine
Mark E. Splaine
DMDavid J. Malenka
David J. Malenka
Background—: Contrast-induced acute kidney injury (CI-AKI) is associated with increased morbidity and mortality after percutaneous coronary interventions and is a patient safety objective of the National Quality Forum. However, no formal quality improvement program to prevent CI-AKI has been conducted. Therefore, we sought to determine whether a 6-year regional multicenter quality improvement intervention could reduce CI-AKI after percutaneous coronary interventions. Methods and Results—: We conducted a prospective multicenter quality improvement study to prevent CI-AKI (serum creatinine increase ≥0.3 mg/dL within 48 hours or ≥50% during hospitalization) among 21 067 nonemergent patients undergoing percutaneous coronary interventions at 10 hospitals between 2007 and 2012. Six intervention hospitals participated in the quality improvement intervention. Two hospitals with significantly lower baseline rates of CI-AKI, which served as benchmark sites and were used to develop the intervention, and 2 hospitals not receiving the intervention were used as controls. Using time series analysis and multilevel poisson regression clustering to the hospital level, we calculated adjusted risk ratios for CI-AKI comparing the intervention period to baseline. Adjusted rates of CI-AKI were significantly reduced in hospitals receiving the intervention by 21% (risk ratio, 0.79; 95% confidence interval: 0.67–0.93; P =0.005) for all patients and by 28% in patients with baseline estimated glomerular filtration rate <60 mL/min per 1.73 m 2 (risk ratio, 0.72; 95% confidence interval: 0.56–0.91; P =0.007). Benchmark hospitals had no significant changes in CI-AKI. Key qualitative system factors associated with improvement included multidisciplinary teams, limiting contrast volume, standardized fluid orders, intravenous fluid bolus, and patient education about oral hydration. Conclusions—: Simple cost-effective quality improvement interventions can prevent ≤1 in 5 CI-AKI events in patients with undergoing nonemergent percutaneous coronary interventions.